Video
Monday Takeaways: It’s All About Nvidia
NVIDIA’s earnings could move markets big this week. Stay cautious, watch volatility, and be smart with your trades. Key takeaways inside!
This Biotech Has a Tech Company’s DNA
Most biotechs burn cash, but this one’s turning heads with its 34.8x return on invested capital and PE ratio of 18.6x – well below industry average.
Buy This, Not That: Intel’s Pain Is This Stock’s Gain
As semiconductor giants circle Intel’s assets, one emerges as the clear winner for investors – but it’s not the obvious choice.
Dealmaker’s Diary: Why This $1.5B Stock Buyback Matters
Beyond the headlines about a major hedge fund stake, this tech giant’s metrics suggest significant upside ahead.
Buy This, Not That: Super Bowl’s Big Winners (It’s Not Who You Think)
The real competition wasn’t on the field – it was during commercial breaks. Here’s what these epic ads tell us about two major stocks.
Market Check: Why I’m Not Worried (Yet)
Markets remain inches from record highs despite recent weakness. While the Magnificent Seven show concerning divergence, we haven’t seen a 5% correction since fall.
Dealmaker’s Diary: Don’t Let This Common Metric Cost You Money
Traditional valuation metrics can mislead investors. Here’s how to look beyond simple ratios for better returns.
Buy This, Not That: This Automaker’s 6% Dividend Is Too Good to Pass Up
While one auto giant trades near highs, another offers an attractive dividend and ideal entry point.
Monday Takeaways: A Triple Threat of Tariffs, Tech, and Trading Pressure
Earnings season is heating up… as is Trump’s tariff war. Shah knows how to play it safe…
Dealmaker’s Diary: A Double Dose of Tickers
By reader request, Alpesh rates a cutting-edge biotech with 232% potential upside and a semiconductor giant with low volatility.